JENBURPH share price, P/E, ROE & financials

On 6 Nov 2026, Jenburkt Pharmaceuticals was priced at ₹940.95, or 12.6× trailing earnings, against an industry P/E of 28.7×, and the shares are 12% below their 52-week high. Its ROCE of 23% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 7.3% and 12% a year over 3 years. It has almost no debt, and its dividend yield is 2.3%. It is a small-cap company with a market cap of ₹415 Cr, ranked 83rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 10% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹917.60
Day high: ₹948.40
Day low: ₹917.60
Prev. close: ₹944.00
Volume: 207

Health check

3 good · 1 fair · 2 to check

ReturnsBehind
−10.2% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 12.6 vs industry 28.7.
GrowthSteady
Sales +7.3%, profit +12.2% a year over 3 years.
ProfitabilityStrong
ROCE 23.1% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
Red flags2 to check
Quarterly profit down 24.5% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹415 Cr, #83 of 154 in its industry by size.

Defensive

Beta 0.40 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹169 Cr · profit ₹33 Cr

Market cap: ₹415 Cr; Small cap
P/E: 12.6; Industry 28.7
Price to book: 2.11; Peers 4.99
Dividend yield: 2.32%
ROE: 18.8%; Peers 14.7%
ROCE: 23.1%; Peers 17.9%
Debt to equity: 0.01; Debt ₹2.49 Cr
EPS (TTM): ₹74.39; Face value ₹10
OPM (TTM): 15.2%; Net margin 19.5%
Sales growth: 0.0%; Latest quarter vs a year ago
Profit growth: −24.5%; Latest quarter vs a year ago
Price to sales: 2.46; EV/EBITDA 8.3

Strengths

Return on equity of 18.8%.
Return on capital employed of 23.1%.
Practically debt-free.
Dividend yield of 2.32%.
P/E of 12.6 against an industry P/E of 28.7.

Risks to check

Quarterly profit down 24.5% on a year ago.
Quarterly sales down 0.0% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It…

Headquarters: Mumbai
Employees: 801
Sector: Healthcare
ISIN: INE354A01013
Website: jenburkt.com

Price range

52 weeks

₹845.00₹1,073.90

Today

₹917.60₹948.40

Avg volume (3M): 1.7K
1-year return: minus 10.2%
From 52-week high: minus 12.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
JENBURPHJenburkt Pharmaceuticals	940.95	minus 0.32%	415	12.6	2.11	23.1%	18.8%	15.2%	7.3%	12.2%	2.32%	minus 10.2%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
41	35.5	–	43	44.6	35.5
–	–	–	–	+8.7%	minus 0.0%
30.2	26.6	–	35.6	30.4	29.5
10.9	9	–	7.4	14.2	6
26.5%	25.2%	–	17.3%	31.9%	17.0%
1.9	2.1	–	1.8	4.3	1.5
0.1	0.1	–	0.1	0.1	0.1
0.8	0.7	–	0.8	0.8	0.6
–	–	–	–	−4	–
11.8	10.2	–	8.3	13.7	6.8
27.9%	23.5%	–	28.5%	20.9%	13.1%
8.5	7.8	–	5.9	10.8	5.9
–	–	–	–	+27.1%	minus 24.5%
–	17.66	23.03	13.44	24.58	13.34

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +7.3%
Profit CAGR 3Y: +12.2%
EPS CAGR 3Y: +13.4%
ROE: 18.8%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
136	142	151	168
–	+4.0%	+6.9%	+11.2%
106	109	111	125
30.4	33.1	40.4	43.7
22.3%	23.4%	26.7%	26.0%
4.9	4.5	5.8	7.8
0.3	0.2	0.4	0.4
2.3	2.3	2.7	3.1
0.2	0.1	0.9	−1.5
32.9	35.2	43.9	46.5
25.1%	26.2%	27.0%	25.3%
24.6	26	32.1	34.7
–	+5.6%	+23.4%	+8.3%
53.90	58.86	72.65	78.71

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.4	4.4	4.4	4.4
118	141	167	193
2.9	–	3.9	2.5
16.5	20.2	20.5	26.5
142	165	196	226
22.7	36.5	56.6	65.3
14	28.2	43.7	47.7
34.4	17.4	76.5	58.1
49.5	74	23.1	47.3
21.1	9	−3.8	7.6
142	165	196	226

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
17.1	8.1	27.9	26.5
2.6	−0.6	−17	−19.5
−21	−7.1	−7.6	−8.9
−1.4	0.5	3.2	−1.8
−2.1	−2.6	−19.7	−13.7
14.9	5.6	8.2	12.8
−5.5	−6.3	−6.8	−7.9

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 5.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you